Medical Marijuana, Inc. (MJNA) has seen numerous successes in reaching out to the Latin American market share of the CBD industry. In addition to being the first cannabis company to be traded publicly on the United States market, MJNA is a leader in the mission to make CBD hemp oil products available to patients in Latin America. As of Aug. 21, 2017, MJNA announced that the Mexican government purchased CBD oil formulations from the Real Scientific Hemp Oil line. This is a landmark decision as the HempMeds Mexico subsidiary will be providing products to treat those with both Lennox-Gastaut Syndrome and Refractory Epilepsy.
Approval in Mexico
The Mexican government’s recent decision to approve the use of medical marijuana has opened up a wide range of possibilities for thousands of patients across the nation. The products offered by Medical Marijuana, Inc. have significant potential for the treatment of conditions such as Parkinson’s, Alzheimer’s, Autism, Epilepsy, Psoriasis, chronic pain, cancer-related pain, fibromyalgia and many others. Conventional treatment options are often ineffective for these conditions, offering only partial relief from symptoms while being accompanied by an array of harmful side effects. Because RSHO-X’s products do not result in debilitating side effects or carry the risk of addiction, they are ideal for use by a broader group of consumers.
Refractory Epilepsy and Lennox-Gastaut Syndrome
Refractory Epilepsy is characterized by seizures that are not responsive to drug therapy. These seizures occur frequently and are usually severe enough to disrupt the patient’s quality of life. Lennox-Gastaut Syndrome is characterized by the occurrence of various types of seizures. Sufferers may also experience developmental impairment and seizures that do not respond to medication. This means that patients with either condition face severely limited treatment options, which makes improved access to CBD oil treatments all the more important. RSHO-X has already changed the life of a 9-year-old girl in Mexico who suffers from severe Lennox-Gastaut Syndrome, and MJNA’s products have given hope to thousands of other patients around the world.
CBD and Seizure Treatment Options
Medical Marijuana, Inc.’s subsidiary, HempMeds Mexico, is the first company to obtain a purchase agreement with the Mexican Government for CBD products. Cannabinoids are known for their medicinal benefits in a variety of treatment indications, and MJNA has had numerous studies performed on the products in its flagship RSHO-X line. CBD oil is especially effective in the treatment of medical conditions that are not responsive to conventional prescription drugs, according to MJNA CEO, Dr. Stuart Titus.
According to a research study by Dr. Saul Garza Morales, a pediatric neurologist from Mexico, RSHO-X products are highly effective in the treatment of epilepsy among pediatric patients. In a study of 29 pediatric patients, Dr. Morales found that 86 percent of the patients benefited from a dramatic reduction in the frequency of their seizures. MJNA will continue to offer high-quality, THC-free products for patients in Latin America suffering from a variety of debilitating medical conditions.
Why Zero-THC Formulation Matters
One of the hallmarks of the RSHO-X product line is that it is formulated without THC. This means that the product is ideal for pediatric patients and others who require the life-changing benefits CBD hemp oil products can provide but do not want to experience the “high” associated with other medical marijuana products. Patients who take RSHO-X formulations can go about their regular activities without impairment, meaning that CBD treatment is not disruptive like many conventional treatments so often are. In addition to being the first cannabis product company to receive import permissions from the Mexican government, the RSHO-X product line is also the first of its kind to meet the World Anti-Doping standards of approval. Not only is the product available to a wider audience, it is considered safe enough for Olympic participants to use as well.
The ExpoWeed Conference
As attitudes toward medical marijuana within the Mexican government continue to change, education is more important now than ever. For this reason, MJNA exhibited its flagship products at the ExpoWeed Conference. The Mexican branch of the ExpoWeed Conference is dedicated to educating both healthcare providers and medical marijuana consumers on the various products within the cannabis industry. Since its inception in 2012, the conference has offered attendees the chance to visit workshops and lectures from industry leaders around the world.
HempMeds Mexico was featured in a recent issue of Vanity Fair Mexico detailing the numerous medicinal benefits of the company’s product lines. Dr. Carlos Gonzalez, the company COO, explained his company’s role in the changing landscape of the cannabis market. As the company continues to receive attention from the international press for its highly effective products, knowledge about the benefits of CBD oil will spread. The legalization of medical marijuana in Mexico opens the door for significant innovation in the future as MJNA is able to offer even more of its product lines to Mexican consumers.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/